ABCG2 and acute myeloid leukemia: Finally, venetoclax, a bcl-2 inhibitor used in lymphoproliferative disease and in elderly AML patients in combination with hypomethylating agents, seems to inhibit the efflux function in wild-type ABCG2 in cell lines [150].